Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL 36 Debt-to-EBITDA is 3.44 as of Mar. 2026. GuruFocus rates BKK:EFORL with a GF Score™ of 36/100 and a GF Value™ of ฿0.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 90 Medical Distribution companies, E For L Aim PCL ranks better than 55.56% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for E For L Aim PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:EFORL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -14.59 Med: -0.06 Max: 5.14
Current: 2.26
During the past 13 years, the highest Debt-to-EBITDA Ratio of E For L Aim PCL was 5.14. The lowest was -14.59. And the median was -0.06.
BKK:EFORL's Debt-to-EBITDA is ranked better than 55.56% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs BKK:EFORL: 2.26
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
E For L Aim PCL Debt-to-EBITDA Related Terms
E For L Aim PCL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for E For L Aim PCL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:EFORL vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, E For L Aim PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
E For L Aim PCL (BKK:EFORL) has a Debt-to-EBITDA of 3.44 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on E For L Aim PCL. According to the industry distribution chart, E For L Aim PCL ranks #40 out of 90 companies in the Medical Distribution industry, placing it in the top 44.4%.
Is E For L Aim PCL's Debt-to-EBITDA too high?
E For L Aim PCL's current Debt-to-EBITDA is 3.44. The Medical Distribution industry median Debt-to-EBITDA is 2.45. E For L Aim PCL's value of 3.44 is 40.4% above this industry median. Based on the distribution chart, E For L Aim PCL ranks #40 out of 90 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, E For L Aim PCL has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #40 out of 90 companies for Debt-to-EBITDA. This puts E For L Aim PCL in the upper half of its industry. The industry median Debt-to-EBITDA is 2.45. E For L Aim PCL's value of 3.44 is 40.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. E For L Aim PCL's current Debt-to-EBITDA of 3.44 is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on E For L Aim PCL. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current Debt-to-EBITDA is 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.15, compared to a current price of ฿0.12 — trading 20% below its estimated fair value. The current Debt-to-EBITDA is 3.44 and 40.4% above the Medical Distribution industry median of 2.45. E For L Aim PCL's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL), the current Debt-to-EBITDA is 3.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 20% below its estimated GF Value™ of ฿0.15.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL:
Debt-to-EBITDA: 3.44
GF Value™: ฿0.15 vs. price of ฿0.12 (20% below fair value)
Industry Position: 40.4% above the Medical Distribution median (#40 of 90)
No single metric tells the full story. See the BKK:EFORL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
36GF Score
Get the complete analysis for BKK:EFORL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL has been successfully added to your 
